Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 10
Submit an article Journal homepage
120
Views
2
CrossRef citations to date
0
Altmetric
Theme: Lung Cancer - Reviews

Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective

Nicolas GirardDepartment of Respiratory medicine, Thoracic Oncology, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University, Lyon, France+33 47 235 7652+33 47 235 [email protected]
Pages 1193-1206 | Published online: 10 Jan 2014

References

  • American Cancer Society. Cancer Facts and Figures 2007. American Cancer Society, Atlanta, GA (2007).
  • Gabrielson E. Worldwide trends in lung cancer pathology. Respirology 11(5), 533–538 (2006).
  • Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543–3551 (2008).
  • Paz-Ares L, de Marinis F, Dediu M et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 31(23), 2895–2902 (2013).
  • Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92–98 (2002).
  • Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 438(7070), 967–974 (2005).
  • Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6(4), 273–286 (2007).
  • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669–676 (2003).
  • Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18(2), 338–340 (2004).
  • Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin. Proc. 81(9), 1241–1257 (2006).
  • Enge M, Bjarnegård M, Gerhardt H et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 21(16), 4307–4316 (2002).
  • Hellström M, Kalén M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14), 3047–3055 (1999)
  • Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr. Cancer Drug Targets 9(5), 639–651 (2009).
  • Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16(2), 159–178 (2005).
  • Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57(5), 963–969 (1997).
  • Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51(2), 143–158 (2006)
  • Lara PNJr, Douillard JY, Nakagawa K et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol. 29(22), 2965–2971 (2011).
  • Ramlau R, Gorbunova V, Ciuleanu TE et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J. Clin. Oncol. 30(29), 3640–3647 (2012).
  • Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J. Surg. Oncol. 24(10), 170 (2012).
  • Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93(25), 14765–14770 (2006).
  • Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88(12), 1979–1986 (2003).
  • Van der Veldt AA, Lubberink M, Bahce I et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21(1), 82–91 (2012).
  • Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19(3), 843–850 (2001).
  • Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184–2191 (2004).
  • Planchard D. Bevacizumab in non-small-cell lung cancer: a review. Expert Rev. Anticancer Ther. 11(8), 1163–1179 (2011).
  • Patel JD, Hensing TA, Rademaker A et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 27(20), 3284–3289 (2009).
  • Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542–2550 (2006).
  • Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann. Oncol. 21(9), 1804–1809 (2010).
  • Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 27(8), 1227–1234 (2009).
  • Socinski MA, Patel JD, Garon EB et al. A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results. J. Clin. Oncol. 31( Suppl.), Abstract 8004 (2013).
  • Barlesi F, Scherpereel A, Rittmeyer A et al. Randomized Phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J. Clin. Oncol. 31(24), 3004–3011(2013).
  • Niho S, Kunitoh H, Nokihara H et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76(3), 362–367 (2012).
  • Soria JC, Mauguen A, Reck M et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann. Oncol. 24(1), 20–30 (2013).)
  • Botrel TE, Clark O, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung Cancer 74(1), 89–97 (2011).
  • Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE 6(8), e22681 (2011).
  • Socinski MA, Evans T, Gettinger S et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl.), e341S–368S (2013).
  • Peters S, Adjei AA, Gridelli C et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23( Suppl. 7), vii56–64 (2012).
  • Crinò L, Dansin E, Garrido P et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 11(8), 733–740 (2010).
  • Lynch TJ, Jahanzeb M, Spigel DR et al. Cumulative exposure to bevacizumab after disease progression correlates with survival in non-small cell lung cancer: a time-dependent analysis of the ARIES observational cohort study. Eur. Soc. Med. Oncol. Abstract 1579 (2012).
  • Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J. Clin. Oncol. 26(1), 60–65 (2008).
  • Laskin J, Crinò L, Felip E et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J. Thorac. Oncol. 7(1), 203–211 (2012).
  • Langer CJ, Socinski MA, Patel JD et al. Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials. J. Clin. Oncol. 31( Suppl.), Abstract 8073 (2013).
  • Schuette W, Nagel S, Schneider CP et al. 65 plus: a randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). J. Clin. Oncol. 31( Suppl.), Abstract 8013 (2013).
  • Sandler AB, Schiller JH, Gray R et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J. Clin. Oncol. 27(9), 1405–1412 (2009).
  • Barlési F, Balleyguier C, Besse B et al. Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Ann. Oncol. 21(8), 1682–1686 (2010).
  • Herman SJ, Winton TL, Weisbrod GL, Towers MJ, Mentzer SJ. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology 190(3), 841–846 (1994).
  • Socinski MA, Langer CJ, Huang JE et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 27(31), 5255–5261 (2009).
  • Besse B, LeMoulex S, Senellart H et al. Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN). J. Clin. Oncol. 31( Suppl.) Abstract 8059 (2013).
  • Thatcher N, Garrigo Lopez P, Pavlakis N et al. Cumulative exposure to bevacizumab maintenance after induction therapy and survival in advanced non-small cell lung cancer: a time-dependent analysis from the SAIL (MO19390) study. Eur. Soc. Med. Oncol. Abstract 1519 (2012).
  • Lopez-Chavez A, Young T, Fages S et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 study: results of an exploratory analysis. J. Thorac. Oncol. 7(11), 1707–1712 (2012).
  • Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62(16), 4645–4655 (2002).
  • Wong HL, de Boer RH. Vandetanib for the treatment of non-small-cell lung cancer. Expert Opin. Pharmacother. 12(14), 2271–2278 (2011).
  • Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9(4), 1546–1556 (2003).
  • Heymach JV, Paz-Ares L, De Braud F et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 26(33), 5407–5415 (2008).
  • Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J. Clin. Oncol. 25(27), 4270–4277 (2007).
  • Blackhall FH, O'brien M, Schmid P et al. A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J. Thorac. Oncol. 5(8), 1285–1288 (2010).
  • Holden SN, Eckhardt SG, Basser R et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. 16(8), 1391–1397 (2005).
  • Herbst RS, Sun Y, Eberhardt WE et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 11(7), 619–626 (2010).
  • de Boer RH, Arrieta Ó, Yang CH et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 29(8), 1067–1074 (2011).
  • Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Shi Y, Song Y. Chemotherapy plus vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials. Clin. Oncol. (R. Coll. Radiol.) 25(1), e7–e15 (2013).
  • Natale RB, Thongprasert S, Greco FA et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 29(8), 1059–1066 (2011).
  • Lee JS, Hirsh V, Park K et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J. Clin. Oncol. 30(10), 1114–1121 (2012).
  • Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature 441(7092), 457–462 (2006).
  • Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099–7109 (2004).
  • Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am. J. Pathol. 169(5), 1875–1885 (2006).
  • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2(5), 471–478 (2003).
  • BlumenscheinJrGR, Gatzemeier U, Fossella F et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J. Clin. Oncol. 27(26), 4274–4280 (2009).
  • Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with nonsmall cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J. Clin. Oncol. 26, 15S (2008).
  • Scagliotti G, Novello S, von PJ et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28(11), 1835–1842 (2010).
  • Wozniak A. Challenges in the current antiangiogenic treatment paradigm for patientswith non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 82(2), 200–212 (2012).
  • Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol. 26(4), 650–656 (2008).
  • Novello S, Scagliotti GV, Rosell R et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br. J. Cancer. 101(9), 1543–1548 (2009).
  • Goss GD, Arnold A, Shepherd FA et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J. Clin Oncol. 28(1), 49–55 (2010).
  • Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 14(22), 7272–7283 (2008).
  • Tan E, Salgia R, Besse B et al. ABT-869 in non-small cell lung cancer (NSCLC): interim results. J. Clin. Oncol. 27(15S), 8074 (2009).
  • Blumenschein GR, Kabbinavar FF, Menon H et al. Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28(15s), 7528 (2010).
  • Hilberg F, Roth GJ, Krssak M et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68(12), 4774–4782 (2008).
  • Roth GJ, Heckel A, Colbatzky F et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem. 52(14), 4466–4480 (2009).
  • Stopfer P, Rathgen K, Bischoff D et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 41(4), 297–311 (2011).
  • Mross K, Stefanic M, Gmehling D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin. Cancer Res. 16(1), 311–319 (2010).
  • Lee CP, Taylor NJ, Attard G et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). J. Clin. Oncol. 24(18S), Abstract 3015 (2006)
  • Okamoto I, Kaneda H, Satoh T et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol. Cancer Ther. 9(10), 2825–2833 (2010).
  • Doebele RC, Conkling P, Traynor AM et al. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann. Oncol. 23(8), 2094–2102 (2012).
  • Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin. Cancer Res. 16(10), 2881–2889 (2010).
  • Daga H, Takeda K, Okada H et al. Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): a phase I study. J. Clin. Oncol. 31( Suppl.), Abstract 8056 (2013).
  • Reck M, Kaiser R, Eschbach C et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann. Oncol. 22(6), 1374–1381 (2011).
  • Hanna NH, Kaiser R, Sullivan RN et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J. Clin. Oncol. 31( Suppl.), Abstract 8034 (2013).
  • Reck M, Kaiser R, Mellemgaard A et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. J. Clin. Oncol. 31( Suppl.), Abstract LBA8011 (2013).
  • Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12(3), 175–180 (2010).
  • Hashemi-Sadraei N, Pennell NA. Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all? Curr. Treat Options Oncol. 3(4), 478–490 (2012).
  • Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(11), 2544–2555 (2005).
  • Herbst RS, Ansari R, Bustin F et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377(9780), 1846–1854 (2007).
  • Herbst RS, O'Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 25(30), 4743–4750 (2007).
  • Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589–1597 (2004).
  • Xiang QF, Wang F, Su XD et al. Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cell. Oncol. (Dordr). 34(1), 33–44 (2011).
  • Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J. Clin. Oncol. 28(6), 949–954 (2010).
  • Tacelli N, Santangelo T, Scherpereel A et al. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur. Radiol. 23(8), 2127–2136 (2013).
  • Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 117(17), 3889–3899 (2011).
  • Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin. Cancer Res. 14(5), 1407–1412 (2008).
  • Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 26(28), 4672–4678 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.